GF Xinde is a direct investment brokerage in China.
GF Xinde Investment Management Co., Ltd. was established in 2008 through the approval of the China Securities Commission on Direct Investment, with registered capital of RMB 2.3 billion. GF Xinde is one of the leading direct investment brokerages in China. Through a deep understanding of capital markets, known for integrity, professional service, and possessing an abundance of industry resources; GF Xinde not only provides strong financial support to investing corporations, but imparts a wealth of advanced management experience and access to a national business network. Supported by the comprehensive strengths of GF Securities, GF Xinde will assist the invested enterprise with establishing a strategic, long-term plan for growth by increasing their management efficiency, building the ideal capital structure, and a strong platform necessary for a successful IPO. All possible types of investments, merger and acquisitions, business, and technical cooperation opportunities will be provided for the invested enterprise. This will ensure the mutual benefits of both the Company and the invested enterprise are financially sound and increase the overall investment value through business synergies.As a direct investment brokerage, GF Xinde provides distinct advantages in regards to investment resources, market research, professional expertise, mergers and acquisitions and IPO experience. As of December 2014, GF Xinde’s accumulated total assets under management exceeded RMB 5 billion, with 16 successful IPOs, ranking first amongst the industry in both scale and number of successful public offerings.Currently, the Company has successfully created a number of diverse management funds: mezzanine funds, merger and acquisition funds, private equity funds, and other investment funds, covering but not limited to a wide range of industries, such as medicine, consumer stocks, and the internet.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 5, 2021
WM Motor
|
Series D | $305M | Automotive | — |
Feb 26, 2020
Cyagen Biosciences
|
Series B | $41M | Biotechnology | — |